{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:56:02Z","timestamp":1792014962294,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":410,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.modpat.2022.100081","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:47:24Z","timestamp":1673311644000},"page":"100081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas"],"prefix":"10.1016","volume":"36","author":[{"given":"Lucy M.","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar Wan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunay","family":"Uludag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"Seider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin R.","family":"Afshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele M.","family":"Bloomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2548-8359","authenticated-orcid":false,"given":"Melike","family":"Pekmezci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2022.100081_bib1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.modpat.2022.100081_bib2","article-title":"Uveal melanoma","volume":"2011","author":"Papastefanou","year":"2011","journal-title":"J\u00a0Skin Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2022.100081_bib3","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3892\/ijo.2020.5140","article-title":"Update on uveal melanoma: translational research from biology to clinical practice (Review)","volume":"57","author":"Ortega","year":"2020","journal-title":"Int J Oncol"},{"issue":"19","key":"10.1016\/j.modpat.2022.100081_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197172","article-title":"Iris colour and the risk of developing uveal melanoma","volume":"21","author":"Houtzagers","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.modpat.2022.100081_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/OPTH.S120530","article-title":"Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012)","volume":"11","author":"Mahendraraj","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"10.1016\/j.modpat.2022.100081_bib6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5114\/jcb.2017.70986","article-title":"Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis","volume":"9","author":"Rao","year":"2017","journal-title":"J\u00a0Contemp Brachytherapy"},{"issue":"9","key":"10.1016\/j.modpat.2022.100081_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamaophthalmol.2018.2466","article-title":"Survival rates in patients after treatment for metastasis from uveal melanoma","volume":"136","author":"Lane","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.modpat.2022.100081_bib8","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28","volume":"124","year":"2006","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.modpat.2022.100081_bib9","first-page":"102","article-title":"Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma","volume":"30","author":"Masoomian","year":"2018","journal-title":"J\u00a0Curr Ophthalmol"},{"issue":"3","key":"10.1016\/j.modpat.2022.100081_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/ICU.0000000000000051","article-title":"Recent developments in prognostic and predictive testing in uveal melanoma","volume":"25","author":"Field","year":"2014","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"10.1016\/j.modpat.2022.100081_bib11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5301\/ejo.5000200","article-title":"Influence of age on prognosis of young patients with uveal melanoma: a matched retrospective cohort study","volume":"23","author":"Kaliki","year":"2013","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"10.1016\/j.modpat.2022.100081_bib12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1016\/j.modpat.2022.100081_bib13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0002-9394(98)00040-3","article-title":"Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6","volume":"125","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.modpat.2022.100081_bib14","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ophtha.2008.04.025","article-title":"Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability","volume":"115","author":"Coupland","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.modpat.2022.100081_bib15","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1167\/iovs.13-13670","article-title":"The prognostic value of extraocular extension in relation to monosomy 3 and gain of chromosome 8q in uveal melanoma","volume":"55","author":"van Beek","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.modpat.2022.100081_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0046-8177(82)80116-0","article-title":"Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis","volume":"13","author":"McLean","year":"1982","journal-title":"Hum Pathol"},{"key":"10.1016\/j.modpat.2022.100081_bib17","series-title":"AJCC Cancer Staging Manual","first-page":"805","article-title":"Chapter 67: Uveal melanoma. Ophthalmic sites:Part XV","author":"Kivel\u00e4","year":"2017"},{"issue":"23","key":"10.1016\/j.modpat.2022.100081_bib18","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"7229","key":"10.1016\/j.modpat.2022.100081_bib19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.modpat.2022.100081_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/gcc.22541","article-title":"Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma","volume":"57","author":"Patrone","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.modpat.2022.100081_bib21","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzyigitoglu","year":"2016","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.modpat.2022.100081_bib22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.modpat.2022.100081_bib23","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1167\/iovs.11-8697","article-title":"Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis","volume":"53","author":"van den Bosch","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.modpat.2022.100081_bib24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/PAS.0000000000000645","article-title":"Comparing the prognostic value of BAP1 mutation pattern, chromosome 3 status, and BAP1 immunohistochemistry in uveal melanoma","volume":"40","author":"van de Nes","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2022.100081_bib25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.modpat.2022.100081_bib26","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/bjc.2014.417","article-title":"Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing","volume":"111","author":"Kalirai","year":"2014","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.modpat.2022.100081_bib27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaophthalmol.2016.0903","article-title":"Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes","volume":"134","author":"Decatur","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.modpat.2022.100081_bib28","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.modpat.2022.100081_bib29","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1136\/bjophthalmol-2014-305047","article-title":"Prognostic parameters in uveal melanoma and their association with BAP1 expression","volume":"98","author":"van Essen","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"6009","key":"10.1016\/j.modpat.2022.100081_bib30","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.modpat.2022.100081_bib31","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"37","key":"10.1016\/j.modpat.2022.100081_bib32","doi-asserted-by":"crossref","first-page":"59209","DOI":"10.18632\/oncotarget.10962","article-title":"Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas","volume":"7","author":"Field","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.modpat.2022.100081_bib33","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00417-019-04335-w","article-title":"Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma","volume":"257","author":"Schefler","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.modpat.2022.100081_bib34","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.modpat.2022.100081_bib35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","article-title":"PRAME as a potential target for immunotherapy in metastatic uveal melanoma","volume":"135","author":"Gezgin","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.modpat.2022.100081_bib36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.modpat.2022.100081_bib37","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.1158\/0008-5472.CAN-06-2522","article-title":"A\u00a0causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer","volume":"66","author":"Epping","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.modpat.2022.100081_bib38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cup.12475","article-title":"Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma","volume":"42","author":"Clarke","year":"2015","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.modpat.2022.100081_bib39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ajo.2018.07.045","article-title":"Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma","volume":"195","author":"Cai","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.modpat.2022.100081_bib40","article-title":"PRAME immunoexpression in 275 cutaneous melanocytic lesions: A double institutional experience","volume":"12","author":"Cazzato","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"10.1016\/j.modpat.2022.100081_bib41","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/cup.13958","article-title":"The utility of PRAME staining in identifying malignant transformation of melanocytic nevi","volume":"48","author":"Lohman","year":"2021","journal-title":"J\u00a0Cutan Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2022.100081_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000524051","article-title":"Preferentially expressed antigen in melanoma immunohistochemistry labeling in uveal melanomas","volume":"8","author":"Ahmadian","year":"2022","journal-title":"Ocul Oncol Pathol"},{"issue":"8","key":"10.1016\/j.modpat.2022.100081_bib43","doi-asserted-by":"crossref","first-page":"766","DOI":"10.5858\/arpa.2015-0453-RA","article-title":"Immunohistochemistry as a practical tool in molecular pathology","volume":"140","author":"Sheffield","year":"2016","journal-title":"Arch Pathol Lab Med"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222055211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222055211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:23:18Z","timestamp":1760232198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222055211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0893395222055211"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2022.100081","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2022.100081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100081"}}